Bioconjugated Liquid-Like Solid Enhances Characterization of Solid Tumor - Chimeric Antigen Receptor T Cell Interactions

• Published in: Acta biomaterialia 2023-12, Vol.172, p.466-479
• Main Authors: Nguyen, Duy T., Liu, Ruixuan, Ogando-Rivas, Elizabeth, Pepe, Alfonso, Pedro, Diego, Qdaisat, Sadeem, Nguyen, Nhi Tran Yen, Lavrador, Julia M., Golde, Griffin R., Smolchek, Ryan A., Ligon, John, Jin, Linchun, Tao, Haipeng, Webber, Alex, Phillpot, Simon, Mitchell, Duane A., Sayour, Elias J., Huang, Jianping, Castillo, Paul, Sawyer, W. Gregory
• Format: Article
• Language: English
• Subjects: cancer; CAR T trafficking; chimeric antigen receptor (CAR) T cell; cytotoxicity; Liquid-like solid
• ISSN: 1742-7061; 1878-7568
• DOI: 10.1016/j.actbio.2023.09.042

Chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable success as an immunotherapy for hematological malignancies, and its potential for treating solid tumors is an active area of research. However, limited trafficking and mobility of T cells within the tumor microenvironment (TME) present challenges for CAR T cell therapy in solid tumors. To gain a better understanding of CAR T cell function in solid tumors, we subjected CD70-specific CAR T cells to a challenge by evaluating their immune trafficking and infiltration through a confined 3D microchannel network in a bio-conjugated liquid-like solid (LLS) medium. Our results demonstrated successful CAR T cell migration and anti-tumor activity against CD70-expressing glioblastoma and osteosarcoma tumors. Through comprehensive analysis of cytokines and chemokines, combined with in situ imaging, we elucidated that immune recruitment occurred via chemotaxis, and the effector to target ratio plays an important role in overall antitumor function. Furthermore, through single-cell collection and transcriptomic profiling, we identified differential gene expression among the immune subpopulations. Our findings provide valuable insights into the complex dynamics of CAR T cell function in solid tumors, informing future research and development in this promising cancer treatment approach. The use of the specialized immune cells named CAR T cells to combat cancers has demonstrated remarkable success against blood cancers. However, this success is not replicated in solid tumors, such as brain or bone cancers, mainly due to the physical barriers of these solid tumors. Currently, preclinical technologies do not allow for reliable evaluation of tumor-immune cell interactions. To better study these specialized CAR T cells in this context, we have developed an innovative in vitro three-dimensional model that promises to dissect the interactions between tumors and CAR T cells at the single-cell level. Our findings provide valuable insights into the complex dynamics of CAR T cell function in solid tumors, informing future research and development in this promising cancer treatment approach. [Display omitted]